Geode Capital Management, LLC Gemini Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.31 - $2.01 $1,514 - $2,323	1,156 Added 0.43%	272,271 $446,000
Q2 2022 Aug 12, 2022	SELL	$1.22 - $1.73 $195,456 - $277,163	-160,210 Reduced 37.14%	271,115 $458,000
Q1 2022 May 13, 2022	SELL	$1.29 - $3.08 $15,018 - $35,857	-11,642 Reduced 2.63%	431,325 $599,000
Q4 2021 Feb 11, 2022	SELL	$2.39 - $4.0 $73,535 - $123,072	-30,768 Reduced 6.49%	442,967 $1.29 Million
Q3 2021 Nov 12, 2021	BUY	$3.3 - $6.32 $64,482 - $123,492	19,540 Added 4.3%	473,735 $1.91 Million
Q2 2021 Aug 13, 2021	BUY	$6.32 - $14.02 $1.1 Million - $2.43 Million	173,650 Added 61.9%	454,195 $2.94 Million
Q1 2021 May 12, 2021	BUY	$11.32 - $18.0 $3.18 Million - $5.05 Million	280,545 New	280,545 $3.8 Million

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.